Acura Pharma (NASDAQ: ACUR) announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE